Skip to main content
CODX logo

CODX · Co-Diagnostics, Inc. · Webcasts, Transcripts & Audio

Track CODX — free
$1.08 +0.01 (+0.93%) At close · Oct 1
Market Cap
$6.82M
Shares
6.25M
Volume · Oct 1 141.12K Avg daily vol (3M) 321.31K

Co-Diagnostics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Co-Diagnostics, Inc. (CODX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Earnings call
FY26 · Q2
2026-08-13
Co-Diagnostics, Inc. (CODX) Q2 2026 Earnings Call Transcript
Positive tone Tuberculosis program (India / WHO ERPD) Regulatory pathway & commercialization readiness Saudi Arabia / Comera joint venture
Revenue
$166,131
▲ 2% YoY
Diluted EPS
$-1.46
Gross margin
72.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-14
Co-Diagnostics, Inc. (CODX) Q1 2026 Earnings Call Transcript
Positive tone India / COSERA joint venture Qomira / Saudi Arabia Financial performance and cash
Revenue
$145,954
▲ 190.3% YoY
Diluted EPS
$-4.06
Gross margin
-32.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-31
Co-Diagnostics, Inc. (CODX) Q4 2025 Earnings Call Transcript
Confident tone AI-driven capabilities and platform innovation CoSara India JV and South Asia expansion Co-Dx PCR Pro platform and US FDA submission
Revenue
$263,922*
▲ 76.7% YoY
Gross margin
46.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-13
Co-Diagnostics, Inc. (CODX) Q3 2025 Earnings Call Transcript
Confident tone CoSara SPAC transaction and India joint venture CoMira joint venture in MENA / Saudi Arabia Co-Dx PCR Pro platform and pricing strategy
Revenue
$145,380
▼ 77.3% YoY
Diluted EPS
$-4.80
Gross margin
81.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Co-Diagnostics, Inc. (CODX) Q2 2025 Earnings Call Transcript
Confident tone COVID-19 test clinical evaluation Co-Dx PCR point-of-care platform India and Africa commercial priorities
Revenue
$162,910
▼ 93.9% YoY
Diluted EPS
$-7.00
Gross margin
80.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Co-Diagnostics, Inc. (CODX) Q1 2025 Earnings Call Transcript
Positive tone Co-Dx PCR Platform Development International Markets - India and South Africa COVID-19 Test and FDA Submission
Revenue
$50,277
▼ 89.3% YoY
Diluted EPS
$-7.05
Gross margin
57.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
Co-Diagnostics, Inc. (CODX) Q4 2024 Earnings Call
Revenue
$149,325*
▼ 95.8% YoY
Gross margin
-70.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Co-Diagnostics, Inc. (CODX) Q3 2024 Earnings Call Transcript
Positive tone International expansion and regulatory submissions Tuberculosis (TB) test development FDA 510(k) review for Co-Dx PCR Pro OTC
Revenue
$641,141
▼ 73.9% YoY
Diluted EPS
$-9.60
Gross margin
53.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Co-Diagnostics, Inc. (CODX) Q2 2024 Earnings Call Transcript
Confident tone FDA 510(k) Submission & Regulatory Progress Co-Dx PCR Pro Platform Commercialization Trade Shows & Pre-Commercialization Outreach
Revenue
$2.66M
▲ 1243.2% YoY
Diluted EPS
$-7.50
Gross margin
92.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Co-Diagnostics, Inc. (CODX) Q1 2024 Earnings Call Transcript
Positive tone Co-Dx PCR platform commercialization and FDA submission Manufacturing capacity expansion Upper respiratory multiplex test
Revenue
$467,854
▼ 22.3% YoY
Diluted EPS
$-9.30
Gross margin
49.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-14
Co-Diagnostics, Inc. (CODX) Q4 2023 Earnings Call Transcript
Positive tone Regulatory pathway and FDA review Co-Dx PCR platform and COVID-19 test Other pipeline tests (HPV, multiplex, strep)
Revenue
$3.56M*
▲ 153.7% YoY
Gross margin
16.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Co-Diagnostics, Inc. (CODX) Q3 2023 Earnings Call Transcript
Revenue
$2.46M
▼ 51.8% YoY
Diluted EPS
$-6.00
Gross margin
89.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Co-Diagnostics, Inc. (CODX) Q2 2023 Earnings Call Transcript
Revenue
$197,806
▼ 96.1% YoY
Diluted EPS
$-9.30
Gross margin
-132.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Co-Diagnostics, Inc. (CODX) Q1 2023 Earnings Call Transcript
Revenue
$601,957
▼ 97.3% YoY
Diluted EPS
$-6.00
▼ 158.8% YoY
Gross margin
16.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-16
Co-Diagnostics, Inc. (CODX) Q4 2022 Earnings Call Transcript
Revenue
$1.40M*
▼ 93.1% YoY
Gross margin
63.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Co-Diagnostics, Inc. (CODX) Q3 2022 Earnings Call Transcript
Revenue
$5.09M
▼ 83.1% YoY
Diluted EPS
$-1.20
▼ 110.5% YoY
Gross margin
84.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Co-Diagnostics, Inc. (CODX) Q2 2022 Earnings Call Transcript
Revenue
$5.02M
▼ 81.6% YoY
Diluted EPS
$-2.40
▼ 124.2% YoY
Gross margin
81.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
Co-Diagnostics, Inc. (CODX) Q1 2022 Earnings Call Transcript
Revenue
$22.70M
▲ 13.4% YoY
Diluted EPS
$10.20
▲ 30.8% YoY
Gross margin
85.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-24
Co-Diagnostics, Inc. (CODX) Q4 2021 Earnings Call Transcript
Revenue
$20.40M*
▼ 24.8% YoY
Gross margin
87.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-12
Co-Diagnostics, Inc. (CODX) Q3 2021 Earnings Call Transcript
Revenue
$30.10M
▲ 38% YoY
Diluted EPS
$11.40
▼ 28.3% YoY
Gross margin
89.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Co-Diagnostics, Inc. (CODX) Q2 2021 Earnings Call Transcript
Revenue
$27.36M
▲ 13.8% YoY
Diluted EPS
$9.90
▼ 35.3% YoY
Gross margin
90.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
Co-Diagnostics, Inc. (CODX) Q1 2021 Earnings Call Transcript
Revenue
$20.02M
▲ 1193.1% YoY
Diluted EPS
$7.80
Gross margin
83.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-06
Co-Diagnostics, Inc. (CODX) Q4 2020 Earnings Call Transcript
Revenue
$27.15M*
▲ 24903.4% YoY
Gross margin
84.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-16
Co-Diagnostics, Inc. (CODX) Q3 2020 Earnings Call Transcript
Revenue
$21.82M
▲ 52559.1% YoY
Diluted EPS
$15.90
Gross margin
73.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
Co-Diagnostics, Inc. (CODX) Q2 2020 Earnings Call Transcript
Revenue
$24.04M
▲ 38942.9% YoY
Diluted EPS
$15.30
Gross margin
75.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-15
Co-Diagnostics, Inc. (CODX) Q1 2020 Earnings Call
Revenue
$1.55M
▲ 45444.9% YoY
Diluted EPS
$-1.50
Gross margin
68.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–26 of 26 webcasts
Key facts CIK 1692415 CUSIP 189763204 13F (30d) 1 filings 1 filers Visit website Investor relations